thenagoyaprotocol61919977
Alan Uster / Shutterstock.com
3 November 2014EuropeRichard Bassett and Richard Wells

The Nagoya Protocol and what it means for the EU

The Nagoya Protocol implements an objective of the Convention on Biological Diversity (CBD), which aims to provide an international framework for safeguarding the conservation and sustainability of biodiversity, and in particular genetic resources. The protocol requires that, if a genetic resource, or traditional knowledge (TK) associated with such a resource, is used, consent must be received from the country in which it is found and from any local community that claims custodianship over it. In the rest of this article, we shall refer just to the genetic resource, but it should be understood that TK may be involved as well. The user of the genetic resource must also provide fair compensation based on any benefit that it has received from the genetic resource. This is generally referred to as access and benefit sharing (ABS).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
12 February 2026   The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.
Europe
12 February 2026   UK and European patent attorneys share their initial views after the UK Supreme Court delivered its landmark judgment, which “brings some much‑needed clarity and consistency” to the patentability of AI-related innovations—including those in the medtech industry.
Europe
12 February 2026   The patent community rejoices after the UK Supreme Court's Emotional Perception decision aligns the UK with Europe, paving the way for computer tech companies to protect inventions—including those in the medtech industry.